Topic

Georgia

A collection of 467 issues

How to Get Krystexxa (Pegloticase) Covered by Blue Cross Blue Shield in Georgia: Prior Authorization, Appeals, and State Protections Guide

Answer Box: Getting Krystexxa Covered by Blue Cross Blue Shield in Georgia Fastest path to approval: Submit prior authorization through BCBS provider portal with complete documentation of failed xanthine oxidase inhibitor trials (allopurinol/febuxostat), G6PD test results, and rheumatology evaluation. Georgia's step therapy exception law (§33-24-59.25) requires
7 min read

How to Get Blenrep (Belantamab Mafodotin) Approved by UnitedHealthcare in Georgia: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Blenrep Covered by UnitedHealthcare in Georgia Important: Blenrep (belantamab mafodotin) was withdrawn from the US market in November 2022 and remains unavailable for commercial coverage. Access is limited to clinical trials or GSK's expanded access program. UnitedHealthcare will deny coverage requests outside these pathways. If
5 min read

How to Get Pomalyst (Pomalidomide) Covered by Blue Cross Blue Shield in Georgia: Complete Prior Authorization Guide

Answer Box: Getting Pomalyst Covered by BCBS Georgia Pomalyst (pomalidomide) requires prior authorization from Blue Cross Blue Shield Georgia (Anthem) and must be filled through their specialty pharmacy networks (CarelonRx or BioPlus). To get approved: 1) Your oncologist submits a PA request documenting prior lenalidomide and proteasome inhibitor failure, 2)
5 min read

Work With Your Doctor to Get Lutathera Approved by Blue Cross Blue Shield in Georgia: Complete Prior Authorization Guide

Quick Answer: Blue Cross Blue Shield of Georgia (Anthem BCBS GA) requires prior authorization for Lutathera for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. You'll need SSTR-positive imaging, documented progression on octreotide/lanreotide, and an oncologist's letter of medical necessity. If denied, Georgia allows external review within 60
7 min read